Cognition Therapeutics Inc.
Cognition Therapeutics (Nasdaq: CGTX) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, zervimesine (CT1812), is an oral therapy designed to protect neuronal… From the company’s description.
In fiscal 2025, Cognition Therapeutics Inc. reported a net loss of $23.49M. Operations used $24.59M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cognition Therapeutics Inc. does
In the company’s own words
Cognition Therapeutics (Nasdaq: CGTX) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, zervimesine (CT1812), is an oral therapy designed to protect neuronal synapses by preventing pathogenic protein oligomers from binding to neurons. The company is studying zervimesine in Alzheimer’s disease and dementia with Lewy bodies (DLB), and has completed a Phase 2 study in geographic atrophy associated with dry age-related macular degeneration. Its development programs include a Phase 2 study in mild cognitive impairment and early Alzheimer’s disease, completed Phase 2 studies in mild-to-moderate Alzheimer’s disease and DLB, and an expanded access program for DLB. Cognition retains worldwide rights to zervimesine and has no products approved for commercial sale. Clinical research has received approximately $171 million in cumulative grants, primarily from the National Institute on Aging. The company’s website is https://cogrx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PURCHASE, NY
- Fiscal year end
- December
- CIK
- 1455365
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cognition Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cognition Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cognition Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cognition Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cognition Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”